| Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.83 |
| Cancer |
0 |
0.71 |
| Antineoplastic Drug |
0 |
0.66 |
| Breast |
0 |
0.59 |
| Cancer Risk |
0 |
0.53 |
| Quality of Life |
0 |
0.2 |
| Humanized Monoclonal Antibody |
0 |
0.16 |
| Chemotherapy |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Antibody Drug Conjugates |
0 |
0.08 |
| California |
0 |
0.08 |
| Estrogen |
0 |
0.08 |
| Hodgkin Lymphoma |
0 |
0.08 |
| Intravenous |
0 |
0.08 |
| Menopause |
0 |
0.08 |
| Neoadjuvant Therapy |
0 |
0.07 |
| Tyrosine Kinase Inhibitor |
0 |
0.06 |
| Aromatase Inhibitors |
0 |
0.04 |
| Biopsy |
0 |
0.04 |
| Endocrine Therapy |
0 |
0.04 |
| Florida |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Illinois |
0 |
0.04 |
| Indiana |
0 |
0.04 |
| Kansas |
0 |
0.04 |
| Kentucky |
0 |
0.04 |
| Maryland |
0 |
0.04 |
| Massachusetts |
0 |
0.04 |
| Michigan |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| South Carolina |
0 |
0.04 |
| Tyrosine Kinase |
0 |
0.04 |